Claims for Patent: 9,040,034

Summary for Patent: 9,040,034

Title:	Vitamin functionalized gel-forming block copolymers for biomedical applications
Abstract:	Gel-forming block copolymers were prepared comprising i) a central hydrophilic block consisting essentially of a divalent poly(ethylene oxide) chain and ii) two peripheral monocarbonate or polycarbonate hydrophobic blocks. The hydrophobic blocks comprise one or more vitamin-bearing subunits. The vitamin-bearing subunits comprise a carbonate backbone portion and a side chain comprising a covalently bound form of a vitamin. The gel-forming block copolymers can be used to prepare various biodegradable and/or biocompatible hydrogel and organogel drug compositions, in particular antimicrobial and/or anti-tumor drug compositions. The hydrogel compositions can be suitable for depot injections. Synergistic enhancement of toxicity to microbes was observed with compositions comprising an antimicrobial cationic polymer and an antimicrobial compound.
Inventor(s):	Hedrick; James L. (Pleasanton, CA), Lee; Ashlynn L. Z. (Singapore, SG), Ng; Victor W. L. (Singapore, SG), Yang; Yi Yan (Singapore, SG)
Assignee:	International Business Machines Corporation (Armonk, NY) Agency for Science, Technology and Research (Singapore, SG)
Application Number:	13/859,062
Patent Claims:	1. A drug composition, comprising: about 4 wt.% to about 10 wt.% of a gel-forming block copolymer; a solvent; and about 0.0001 wt.% to about 10 wt.% of a drug; wherein the gel-forming block copolymer has a structure in accordance with formula (1): ##STR00122## wherein d' is a positive number having a value of about 100 to about 600, each K' is an independent divalent linking group selected from the group consisting of 0, NH, S, and combinations thereof, each P.sup.a is an independent monocarbonate or polycarbonate chain comprising 1 to about 10 vitamin-bearing subunits, wherein each of the vitamin-bearing subunits comprises a carbonate backbone portion and a side chain linked to the carbonate backbone portion, the side chain comprising a covalently bound form of a vitamin, Z.sup.a is a first end group selected from the group consisting of hydrogen and groups comprising 1 to about 15 carbons, and Z.sup.b is a second end group selected from the group consisting of hydrogen and groups comprising 1 to about 15 carbons; and wherein weight percent (wt.%) is based on total weight of the drug composition, the drug composition is a gel formed by noncovalent interactions of polymer chains of the block copolymer in the solvent, and the drug is contained in the gel. 2. The drug composition of claim 1, wherein each Pa consists essentially of 1 to about 8 vitamin-bearing subunits. 3. The drug composition of claim 1, wherein the vitamin is selected from the group consisting of vitamin E compounds, vitamin D compounds, and combinations thereof. 4. The drug composition of claim 1, wherein each of the vitamin-bearing subunits comprises an alpha-tocopheryl moiety. 5. The drug composition of claim 1, wherein each of the vitamin-bearing subunits comprises an ergocalcipheryl moiety. 6. The drug composition of claim 1, wherein Z.sup.a is hydrogen and Z.sup.b is hydrogen. 7. The drug composition of claim 1, wherein the vitamin-bearing subunits of have a structure in accordance with formula (2): ##STR00123## wherein the carbonate backbone atoms are numbered 1 to 6, L.sup.d is a single bond or a divalent linking group comprising 1 to about 15 carbons, V' is a moiety comprising a covalently bound form of a vitamin, each R' is an independent monovalent radical selected from the group consisting of hydrogen, halogens, methyl, and ethyl, R'' is a monovalent radical selected from the group consisting of hydrogen and alkyl groups comprising 1 to 6 carbons, t is a positive integer having a value of 0 to 2, t' is a positive integer having a value of 0 to 2, and t and t' cannot both be zero. 8. The drug composition of claim 1, wherein the vitamin-bearing subunits of the gel-forming block copolymer have the structure: ##STR00124## 9. The drug composition of claim 1, wherein each of the vitamin-bearing subunits of the gel-forming block copolymer has the structure: ##STR00125## 10. The drug composition of claim 1, wherein the drug is an anti-tumor agent and the drug composition is suitable for treating a cancer. 11. The drug composition of claim 10, wherein the anti-tumor agent is a mono-clonal antibody. 12. The drug composition of claim 11, wherein the mono-clonal antibody is herceptin. 13. The drug composition of claim 10, wherein the solvent is water, the composition is a hydrogel, and the composition inhibits growth of cancer cells in vivo when administered by a depot injection. 14. A method of treating a cancer, comprising performing an in vivo depot injection of the drug composition of claim 10 near or in contact with a cancerous tumor. 15. The method of claim 14, wherein the cancer is a breast cancer. 16. An antimicrobial drug composition, comprising: about 4 wt.% to about 10 wt.% of a gel-forming block copolymer; a solvent; and about 0.0001 wt.% to about 10 wt.% of an antimicrobial cationic polycarbonate (first drug); wherein the gel-forming block copolymer has a structure in accordance with formula (1): ##STR00126## wherein d' is a positive number having a value of about 100 to about 600, each K' is an independent divalent linking group selected from the group consisting of 0, NH, S, and combinations thereof, each Pa is an independent monocarbonate or polycarbonate chain comprising 1 to about 10 vitamin-bearing subunits, wherein each of the vitamin-bearing subunits comprises a carbonate backbone portion and a side chain linked to the carbonate backbone portion, the side chain comprising a covalently bound form of a vitamin, Z.sup.a is a first end group selected from the group consisting of hydrogen and groups comprising 1 to about 15 carbons, and Z.sup.b is a second end group selected from the group consisting of hydrogen and groups comprising 1 to about 15 carbons; and wherein weight percent (wt.%) is based on total weight of the antimicrobial drug composition, the antimicrobial drug composition is a gel formed by noncovalent interactions of polymer chains of the gel-forming block copolymer in the solvent, the antimicrobial cationic polycarbonate is contained in the gel. 17. The antimicrobial drug composition of claim 16, wherein the antimicrobial cationic polycarbonate has a structure in accordance with formula (8): Z'--P'--Z'' (8), wherein Z' is a monovalent C.sub.1-C.sub.15 is first end group, wherein Z' is linked to a backbone carbonyl group of P', Z'' is a monovalent second end group selected from the group consisting of hydrogen and C.sub.1-C.sub.15 moieties, P' is a polymer chain consisting essentially of cationic carbonate subunits, wherein i) P' has a degree of polymerization (DP) of about 5 to about 45, ii) each of the cationic carbonate subunits comprises a backbone portion and a C.sub.6-C.sub.25 cationic side chain linked to the backbone portion, and iii) the cationic side chain comprises a positive-charged heteroatom Q' of a quaternary ammonium group and/or quaternary phosphonium group, about 25% to about 100% of the cationic carbonate subunits, designated first cationic carbonate subunits, have a cationic side chain comprising 13 to about 25 carbons, and about 0% to about 75% of the cationic carbonate subunits, designated second cationic carbonate subunits, have a cationic side chain comprising 6 to 12 carbons. 18. The antimicrobial drug composition of claim 17, wherein each of the cationic carbonate subunits of the antimicrobial cationic polycarbonate has a structure in accordance with formula (9): ##STR00127## wherein La-Q'(Ra).sub.u, is a C.sub.6-C.sub.25 cationic side chain comprising a quaternary ammonium group and/or quaternary phosphonium group, wherein La is a divalent linking group comprising at least 3 carbons, Q' is a tetravalent positive-charged nitrogen or phosphorus, u' has a value of 1 to 3, each R.sup.a is an independent radical having a valency of 1 to 3, and each R.sup.acomprises at least 1 carbon, each R' is an independent monovalent radical selected from the group consisting of hydrogen, halogens, methyl, and ethyl, R'' is a monovalent radical selected from the group consisting of hydrogen, halogens, and alkyl groups comprising 1 to 6 carbons, t is a positive integer having a value of 0 to 2, t' is a positive integer having a value of 0 to 2, t and t' cannot both be zero, and X' is a negative-charged ion. 19. The antimicrobial drug composition of claim 17, wherein each of the cationic carbonate subunits of the antimicrobial cationic polycarbonate has a structure in accordance with formula (10): ##STR00128## wherein L.sup.b-Q'(Ra).sub.u.sup.1is a C.sub.5-C.sub.24 cationic moiety comprising a quaternary ammonium group and/or quaternary phosphonium group, wherein L.sup.b is a divalent linking group comprising at least 2 carbons, Q' is a tetravalent positive-charged nitrogen or phosphorus, u' has a value of 1 to 3, each R.sup.a is an independent radical having a valency of 1 to 3,and each R.sup.a comprises at least 1 carbon, R'' is a monovalent radical selected from the group consisting of hydrogen, halogens, and alkyl groups comprising 1 to 6 carbons, and X' is a negative-charged ion. 20. The antimicrobial drug composition of claim 17, wherein each of the cationic carbonate subunits of the antimicrobial cationic polycarbonate has a structure in accordance with formula (11): ##STR00129## wherein L.sup.c-Q'(R.sup.a).sub.u.sup.' is a C.sub.5-C.sub.24 cationic moiety comprising a quaternary ammonium group and/or quaternary phosphonium group, wherein L.sup.c is a divalent linking group comprising at least 2 carbons, Q' is a tetravalent positive-charged nitrogen or phosphorus, u' has a value of 1 to 3, and each R.sup.a is an independent radical having a valency of 1 to 3, wherein each R.sup.a comprises at least 1 carbon, each R' is an independent monovalent radical selected from the group consisting of hydrogen, halogens, methyl, and ethyl, R'' is a monovalent radical selected from the group consisting of hydrogen, halogens, and alkyl groups comprising 1 to 6 carbons, and X' is a negative-charged ion. 21. The antimicrobial drug composition of claim 16, wherein the antimicrobial cationic polycarbonate has a structure in accordance with formula (19): Z.sup.c--P.sup.b--C'--P.sup.b--Z.sup.c (19), wherein C' is a C.sub.2-C.sub.15 divalent linking group joining polymer chains P.sup.b, wherein C' comprises i) a first heteroatom linked to a first polymer chain P.sup.b, wherein the first heteroatom is selected from the group consisting of nitrogen, oxygen, and sulfur, and ii) a second heteroatom linked to a second polymer chain P.sup.b, wherein the second heteroatom is selected from the group consisting of nitrogen, oxygen, and sulfur, each Z' is an independent monovalent end group selected from the group consisting of hydrogen and C.sub.1-C.sub.15 moieties, each polymer chain P.sup.b consists essentially of cationic carbonate subunits, wherein i) the cationic polymer comprises a total of 5 to about 45 cationic carbonate subunits, ii) each of the cationic carbonate subunits comprises a backbone portion of the polymer chain and a cationic side chain linked to the backbone portion, and iii) the cationic side chain comprises a positive-charged heteroatom Q' of a quaternary ammonium group and/or quaternary phosphonium group, about 25% to 100% of all the cationic carbonate subunits of the cationic polymer, designated first cationic carbonate subunits, have a cationic side chain comprising 10 to about 25 carbons, and 0% to about 75% of the cationic carbonate subunits of the cationic polymer, designated second cationic carbonate subunits, have a cationic side chain comprising 6 to 9 carbons. 22. The antimicrobial drug composition of claim 21, wherein each of the first cationic carbonate subunits of the antimicrobial cationic polycarbonate has a cationic side chain comprising 13 to about 25 carbons, and each of the second cationic carbonate subunits has a cationic side chain comprising 6 to 12 carbons. 23. The antimicrobial drug composition of claim 16, further comprising a second drug that is an antimicrobial compound. 24. The antimicrobial drug composition of claim 23, wherein the antimicrobial compound is selected from the group consisting of fluconazole, doxycycline, and combinations thereof.

Details for Patent 9,040,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26